109 related articles for article (PubMed ID: 16874014)
1. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Sterba J; Valik D; Mudry P; Kepak T; Pavelka Z; Bajciova V; Zitterbart K; Kadlecova V; Mazanek P
Onkologie; 2006 Jul; 29(7):308-13. PubMed ID: 16874014
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
4. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
7. [Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Hauser P; Vancsó I; Pócza T; Schuler D; Garami M
Magy Onkol; 2013 Dec; 57(4):259-63. PubMed ID: 24353991
[TBL] [Abstract][Full Text] [Related]
8. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.
Kieran MW; Turner CD; Rubin JB; Chi SN; Zimmerman MA; Chordas C; Klement G; Laforme A; Gordon A; Thomas A; Neuberg D; Browder T; Folkman J
J Pediatr Hematol Oncol; 2005 Nov; 27(11):573-81. PubMed ID: 16282886
[TBL] [Abstract][Full Text] [Related]
9. Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Nygaard R; Kivivuori SM
Anticancer Drugs; 2012 Mar; 23(3):342-6. PubMed ID: 22156796
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
11. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
[TBL] [Abstract][Full Text] [Related]
12. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Bowers DC; Aquino VM; Leavey PJ; Bash RO; Journeycake JM; Tomlinson G; Mulne AF; Haynes HJ; Winick NJ
Pediatr Blood Cancer; 2004 Jan; 42(1):93-8. PubMed ID: 14752800
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
[TBL] [Abstract][Full Text] [Related]
15. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
17. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
